Related insights: Healthcare

Thumbnail

Brexit and patents

07 Aug 2020
The European patent regime is not an instrument of the European Union ("EU"). The European Patent Convention 2000 and its various protocols are not part of the accumulated body of EU law. The current membership of the European Patent Office numbers 38 countries, which is a far greater number than the current 28 member states of the EU. As a result, the European patent regime, of which the United Kingdom ("UK") is a part, will remain largely unaffected by Brexit. The UK's membership of the Patent Cooperation Treaty will also remain unaffected.
Thumbnail

UK Supreme Court gives a strict interpretation on the rules of sufficiency

13 Jul 2020
The UK's Supreme Court ("UKSC") has handed down its eagerly awaited judgment in the dispute between Regeneron Pharmaceuticals Inc ("Regeneron") and Kymab Limited ("Kymab").  The invention by Regeneron related to the creation of a type of transgenic mouse (the "VelocImmune") that is more effective in its receipt of human antibody genes, for the production of human antibodies. As such, this genetically modified mouse has been regarded as a major breakthrough in the field of bio pharmaceuticals. Nevertheless, despite such an advancement, the UKSC has held that the patents upon which Regeneron based its innovative platform are invalid for lack of sufficiency because the claims, as construed, would include a range of modified mice, some of which it would not have been possible to produce as at the priority date of February 2001.

COVID-19: managing workplace safety – an update following 100 days in lockdown

13 Jul 2020
At the start of lockdown, the Health and Safety Executive's (HSE) general approach was to work with employers to ensure compliance and to issue enforcement notices to help secure improvements where appropriate. However, as the phased return to work has progressed, the general tone has changed. HSE is now making it plain that prosecution will be a consideration in appropriate cases. It has reported over 1,000 spot checks after it resumed inspections at the end of May.
Thumbnail

WBD advises Puma Private Equity on investment into Tictrac

05 Jun 2020
Womble Bond Dickinson (WBD) has advised Puma Private Equity which led a £6 million equity investment into Tictrac, a leading health engagement company. The corporate team was led by Partner Leon Miller, Managing Associate Alex Fergus and South African qualified lawyer Alice Millar who advised on the transaction.
WBD_Services_Regulatory

COVID-19 impacts go-live date of EU medical device regulation

07 Apr 2020
Following the European Commission's March press release on the suggested postponement of the effective date of the Medical Device Regulation (the MDR), given the impact of the Coronavirus pandemic, it's formal Proposal was published on Friday 3 April. This Preparatory Act, which amends the date of application of various provisions in the MDR from 26 May 2020 to 26 May 2021, has still to be approved by both the European Parliament and the Council.

Keeping workers safe: COVID-19 health and safety FAQs

07 Apr 2020
We previously outlined some of the key questions that we had been asked by businesses in relation to managing the risks of COVID-19 from a health and safety perspective. This note provides an update of the position (as at 3 April 2020) to reflect recent developments which remain under constant review.